Part 7/13:
Amidst increasing scrutiny, the reliability and quality of generic drugs in China have come under fire. The National Healthcare Security Administration (NHSA) and the National Medical Products Administration (NMPA) sought to assuage concerns over the reliability of these drugs following an investigation prompted by doctors in major cities like Beijing and Shanghai. However, findings from independent reports suggest the issue is far from resolved.
Despite claims from regulators that criticisms stem from "anecdotes and subjective feelings," financial media outlet Ta Sin has highlighted persistent discrepancies in publicly disclosed data relating to generic drugs. Reports of statistical errors and data inconsistencies have plagued the sector, further eroding public trust.